Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2015; 21(43): 12421-12429
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12421
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12421
Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy
Ni Li, Jing-Hang Xu, Min Yu, Sa Wang, Chong-Wen Si, Yan-Yan Yu, Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
Author contributions: Si CW and Yu YY designed the research; Xu JH, Wang S, Yu M and Li N collected the data; and Li N analyzed the data and wrote the paper.
Supported by National Science and Technology Major Project, No. 2012ZX10002003.
Institutional review board statement: The study was reviewed and approved by the Peking University First Hospital Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, and there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of the manuscript.
Data sharing statement: No additional data are available
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yan-Yan Yu, PhD, Professor, Department of Infectious Diseases, Peking University First Hospital, No. 8, Xi Shi Ku street, Xicheng District, Beijing 100034, China. yyy@bjmu.edu.cn
Telephone: +86-10-83572081 Fax: +86-10-66551066
Received: May 6, 2015
Peer-review started: May 7, 2015
First decision: June 2, 2015
Revised: June 17, 2015
Accepted: September 2, 2015
Article in press: September 3, 2015
Published online: November 21, 2015
Peer-review started: May 7, 2015
First decision: June 2, 2015
Revised: June 17, 2015
Accepted: September 2, 2015
Article in press: September 3, 2015
Published online: November 21, 2015
Core Tip
Core tip: Long-term entecavir therapy for patients with chronic hepatitis B (CHB) can result in histological improvement and regression of fibrosis substantially. However, the relationship between the serum low level hepatitis B virus (HBV) DNA and fibrosis is unclear for CHB patients with partial virological response to entecavir. Our study found that although the cumulative probabilities of HBV DNA response showed a significant difference between hepatitis B e antigen-positive CHB patients with complete virological response and partial virological response to 144 wk of entecavir treatment, long-term low level HBV DNA did not deteriorate the FIB-4, which was used to evaluate liver fibrosis, by the end of three years.